FULC
NasdaqGMFulcrum Therapeutics, Inc.
Price
Key statistics
Insider activity
SEC EDGAR ↗Showing 13 recent filings. 8 other (grants, option exercises, gifts, tax withholding) are listed below but excluded from buy/sell flow.
| Insider | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|
TANG KEVIN 10% Owner | Buy (open market) | 12.97K | $3.54 | $45,899.64 | 2026-07-13 |
TANG KEVIN 10% Owner | Buy (open market) | 53.65K | $3.56 | $190,997.56 | 2026-07-14 |
TANG KEVIN 10% Owner | Buy (open market) | 75.95K | $3.58 | $271,908.16 | 2026-07-14 |
TANG KEVIN 10% Owner | Buy (open market) | 107.38K | $3.56 | $382,262.12 | 2026-07-15 |
Banks Sonja Director | Grant / award | 32K | $0.00 | — | 2026-06-30 |
Dorton Katina Director | Grant / award | 32K | $0.00 | — | 2026-06-30 |
Gould Robert J Director | Grant / award | 32K | $0.00 | — | 2026-06-30 |
Haviland Kate Director | Grant / award | 32K | $0.00 | — | 2026-06-30 |
King Rachel K. Director | Grant / award | 32K | $0.00 | — | 2026-06-30 |
GERAGHTY JAMES A Director | Grant / award | 32K | $0.00 | — | 2026-06-30 |
Hill Colin Director | Grant / award | 32K | $0.00 | — | 2026-06-30 |
Ezekowitz Alan Director | Grant / award | 32K | $0.00 | — | 2026-06-30 |
Ezekowitz Alan Director | Sell (open market) | 18K | $3.65 | $65,613.60 | 2026-06-26 |
Source: SEC EDGAR Forms 4/4A (CIK 1680581). Click an insider to open the original filing.
Social sentiment
Volume-weighted across live social sources
#INSIDERS $FULC 10% owner Keven Tang (Tang Capital) bought another 249,946 shares at $3.54 - $3.55 worth approximately $891K (transaction dates 7/13-7/15). $HNRG Director bought 5,000 shares at $17.12 - $17.13 worth approximately $86K (transaction date 7/14). $SLGL 10% owner Opaleye Management bought 1,695 shares at $73.34 - $73.95 worth approximately $125K (transaction dates 7/13-7/14). $PB Director sold 1,100 shares worth approximately $80K (transaction date 7/15).
$SPRO CEO of Spero was CFO at $FULC this was the time frame she was there. Looking at their chart to see performance during her time there.
$FULC Insider purchase: https://filingtracker.ai/filing/1178579/0001178579-26-000014?doc=form4-07152026_110717.xml
$FULC You could’ve sold when I alerted and bought back at 3.4 now if you wanted.
$FULC Down to 3.56, you could’ve sold when I alerted and bought back today if you wanted!
$FULC what is co's exit plan? reverse merger?
$FULC Went down to 3.66, you could’ve sold when I alerted…
"someone" is starting to anticipate some news re $FULC the stock is grinding higher since June 18.
Let's hope $SPRO & $GSK lose out on there "next phase of growth" for not acting swiftly and boldly. There is already a clean, willing and able cash shell $FULC in Cambridge with $300 million + cash. FULC was a sickle cell disease failure (unfortunately) but at least the Board MOVES quickly. -- cut 85% of staff; put in retention bonuses for remaining management/employees, cut burn rate drastically, all to drive a reverse merger. Shit is happening in Cambridge, MA.
$FULC Selling time at 4!
$SPRO if Spero and GSK lost its reverse merger partner to say $FULC -- why not just take that Cambridge MA Nasdaq shell that has 300 million plus and a WILLING management and Board? If SPERO / $GSK TOOK TOO LONG AND LOST OUT TO FULCRUM THERAPEUTICS -- WHERE IS THE NEXT GROWTH OPPORTUNITY? IF THERE IS NONE ----- PERHAPS WE DO SEE A TENDER OFFER FROM GSK TONIGHT BEFORE THE AGM IF NO REVERSE MERGER PARTNER, THEN NO NEED FOR 120 MILLION NEW SHARES
$SPRO might have lost reverse merger partner to $FULC ? FULC already clean shell with 300 million in the bank. And they already let go 85% of staff. Only 9 employees vs Spero fat pig at 20+!!! These are all Cambridge Massachusetts outfits. Big competition to land their deals? Esther actually came to Spero from Fulcrum! Lots of people in the know I would guess. These are just wild ass guesses but something don't seem right
Latest news
Fulcrum Therapeutics (FULC) Stock Fair Value Moves Lower After Pociredir Exit
A Look At Fulcrum Therapeutics (FULC) Valuation After Scrapping Lead Sickle Cell Drug And Restructuring
Fulcrum Therapeutics (FULC) Loses 51% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
FULC Stock Crashes as Cancer Risk Forces Its Only Drug Program's End
JPMorgan Downgrades Fulcrum Therapeutics to Underweight From Overweight
Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today?
Top Midday Decliners
This Biotech Stock Plunges 54%. Its Sickle Cell Drug Has ‘No Viable Path Forward.’
Meta Platforms upgraded, Okta downgraded: Wall Street's top analyst calls
Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug
Get insider-buy alerts
Free weekly digest of the most notable SEC insider purchases — plus early access to real-time alerts on your watchlist.